mefloquine hydrochloride has been researched along with Malaria in 27 studies
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study represents the first phase III trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis." | 9.14 | Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. ( Brennan, L; Edstein, MD; Harris, IE; Kerr, C; Kitchener, SJ; Leggat, PA; Nasveld, PE; Ohrt, C; Pickford, P; Prescott, W; Reid, M, 2010) |
| "Sixteen new artemisinin-derived 2-carbon-linked trioxane dimers were prepared to study chemical structure/antimalarial activity relationships (SAR)." | 7.80 | The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether. ( Conyers, RC; Mazzone, JR; Mott, BT; Posner, GH; Siegler, MA; Sullivan, DJ; Tripathi, AK, 2014) |
| "Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P." | 7.77 | In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. ( Anstey, NM; Chalfein, F; Ebsworth, EP; Kenangalem, E; Marfurt, J; Piera, KA; Prasetyorini, B; Price, RN; Ratcliff, A; Russell, B; Siswantoro, H; Tjitra, E; Wuwung, M, 2011) |
| "In an attempt to augment the efficacy of 7-chloro 4-aminoquinoline analogs and also to overcome resistance to antimalarial agents, we synthesized three cyclen (1,4,7,10-tetraazacyclododecane) analogs of chloroquine [a bisquinoline derivative, 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline HBr, and a 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline-Zn(2+) complex]." | 7.75 | Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs. ( Borne, RF; Khan, MO; Khan, SI; Kimura, E; Levi, MS; Tekwani, BL, 2009) |
| "The synthesis of deoxycholic acid (DCA)- and cholic acid (CA)-derived mixed tetraoxanes revealed that N-(2-dimethylamino)ethyl derivatives are potent antimalarials in vitro and in vivo." | 7.74 | Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1). ( Milhous, WK; Milić, D; Opsenica, D; Smith, KS; Solaja, BA; Terzić, N; Tinant, B, 2007) |
| "Using easily accessible keto-trioxanes 7a-g as the starting materials, a series of new variously functionalized 1,2,4-trioxanes 10-36 have been prepared and evaluated for antimalarial activity against multi-drug-resistant Plasmodium yoelii nigeriensis in mice in the dose range of 24 mg/kg x 4 days to 96 mg/kg x 4 days by oral route." | 7.73 | Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice. ( Malik, H; Puri, SK; Singh, C, 2006) |
| "Febrifugine is an alkaloid isolated from Dichroa febrifuga Lour as the active component against Plasmodium falciparum, but exhibits toxic side effects." | 5.38 | Febrifugine analogue compounds: synthesis and antimalarial evaluation. ( Chandrashekar, G; Chatterji, D; Meng, L; Robinson, K; Zhu, S, 2012) |
| "This study represents the first phase III trial of the safety, tolerability, and effectiveness of tafenoquine for malaria prophylaxis." | 5.14 | Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. ( Brennan, L; Edstein, MD; Harris, IE; Kerr, C; Kitchener, SJ; Leggat, PA; Nasveld, PE; Ohrt, C; Pickford, P; Prescott, W; Reid, M, 2010) |
| "Chloroquine (CQ) has been used as first line malaria therapeutic drug for decades." | 3.81 | Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives. ( Caridha, D; Gerena, L; Korotchenko, V; Kreishman-Deitrick, M; Li, Q; Lin, AJ; Sathunuru, R; Smith, PL, 2015) |
| "Sixteen new artemisinin-derived 2-carbon-linked trioxane dimers were prepared to study chemical structure/antimalarial activity relationships (SAR)." | 3.80 | The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether. ( Conyers, RC; Mazzone, JR; Mott, BT; Posner, GH; Siegler, MA; Sullivan, DJ; Tripathi, AK, 2014) |
| "Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P." | 3.77 | In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. ( Anstey, NM; Chalfein, F; Ebsworth, EP; Kenangalem, E; Marfurt, J; Piera, KA; Prasetyorini, B; Price, RN; Ratcliff, A; Russell, B; Siswantoro, H; Tjitra, E; Wuwung, M, 2011) |
| "Drug resistance against dihydrofolate reductase (DHFR) inhibitors-such as pyrimethamine (PM)-has now spread to almost all regions where malaria is endemic, rendering antifolate-based malaria treatments highly ineffective." | 3.76 | Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. ( Brun, R; Chitnumsub, P; Dartois, V; Diagana, TT; Goh, A; Kamchonwongpaisan, S; Keller, TH; Kiara, SM; Lakshminarayana, SB; Ma, NL; Maneeruttanarungroj, C; Nzila, A; Rottmann, M; Taweechai, S; Weaver, M; Wittlin, S; Wong, J; Yeung, BK; Yuthavong, Y; Zou, B, 2010) |
| "In an attempt to augment the efficacy of 7-chloro 4-aminoquinoline analogs and also to overcome resistance to antimalarial agents, we synthesized three cyclen (1,4,7,10-tetraazacyclododecane) analogs of chloroquine [a bisquinoline derivative, 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline HBr, and a 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline-Zn(2+) complex]." | 3.75 | Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs. ( Borne, RF; Khan, MO; Khan, SI; Kimura, E; Levi, MS; Tekwani, BL, 2009) |
| "The synthesis of deoxycholic acid (DCA)- and cholic acid (CA)-derived mixed tetraoxanes revealed that N-(2-dimethylamino)ethyl derivatives are potent antimalarials in vitro and in vivo." | 3.74 | Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1). ( Milhous, WK; Milić, D; Opsenica, D; Smith, KS; Solaja, BA; Terzić, N; Tinant, B, 2007) |
| " Their antimalarial effects have been characterized in parasite assays using chloroquine-sensitive and -resistant strains of Plasmodium, alone or in drug combination, and in the Plasmodium berghei rodent model." | 3.74 | Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum. ( Becker, K; Davioud-Charvet, E; Friebolin, W; Furrer, J; Jannack, B; Lanzer, M; Oeser, T; Sanchez, CP; Wenzel, N; Yardley, V, 2008) |
| "Using easily accessible keto-trioxanes 7a-g as the starting materials, a series of new variously functionalized 1,2,4-trioxanes 10-36 have been prepared and evaluated for antimalarial activity against multi-drug-resistant Plasmodium yoelii nigeriensis in mice in the dose range of 24 mg/kg x 4 days to 96 mg/kg x 4 days by oral route." | 3.73 | Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice. ( Malik, H; Puri, SK; Singh, C, 2006) |
| "Febrifugine is an alkaloid isolated from Dichroa febrifuga Lour as the active component against Plasmodium falciparum, but exhibits toxic side effects." | 1.38 | Febrifugine analogue compounds: synthesis and antimalarial evaluation. ( Chandrashekar, G; Chatterji, D; Meng, L; Robinson, K; Zhu, S, 2012) |
| "Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance." | 1.37 | Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. ( Bathurst, I; Buckner, FS; Burrows, J; Charman, SA; Charman, WN; Creason, S; Deng, X; El Mazouni, F; Floyd, DM; Gujjar, R; Matthews, D; Phillips, MA; Rathod, PK; Shackleford, DM; White, J; White, KL, 2011) |
| " The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity." | 1.37 | Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. ( Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011) |
| " The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model." | 1.36 | Spiroindolones, a potent compound class for the treatment of malaria. ( Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (44.44) | 29.6817 |
| 2010's | 14 (51.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brossi, A | 1 |
| Venugopalan, B | 1 |
| Dominguez Gerpe, L | 1 |
| Yeh, HJ | 1 |
| Flippen-Anderson, JL | 1 |
| Buchs, P | 1 |
| Luo, XD | 1 |
| Milhous, W | 2 |
| Peters, W | 2 |
| Avery, MA | 1 |
| Alvim-Gaston, M | 1 |
| Vroman, JA | 1 |
| Wu, B | 1 |
| Ager, A | 2 |
| Robinson, BL | 1 |
| Charman, W | 1 |
| Nallan, L | 1 |
| Bauer, KD | 1 |
| Bendale, P | 1 |
| Rivas, K | 1 |
| Yokoyama, K | 1 |
| Hornéy, CP | 1 |
| Pendyala, PR | 1 |
| Floyd, D | 1 |
| Lombardo, LJ | 1 |
| Williams, DK | 1 |
| Hamilton, A | 1 |
| Sebti, S | 1 |
| Windsor, WT | 1 |
| Weber, PC | 1 |
| Buckner, FS | 2 |
| Chakrabarti, D | 1 |
| Gelb, MH | 1 |
| Van Voorhis, WC | 1 |
| Zhang, Q | 1 |
| Guan, J | 1 |
| Sacci, J | 1 |
| Ellis, W | 1 |
| Kyle, D | 1 |
| Lin, AJ | 2 |
| Singh, C | 1 |
| Malik, H | 1 |
| Puri, SK | 1 |
| Terzić, N | 1 |
| Opsenica, D | 3 |
| Milić, D | 1 |
| Tinant, B | 1 |
| Smith, KS | 2 |
| Milhous, WK | 2 |
| Solaja, BA | 3 |
| Friebolin, W | 1 |
| Jannack, B | 1 |
| Wenzel, N | 1 |
| Furrer, J | 1 |
| Oeser, T | 1 |
| Sanchez, CP | 1 |
| Lanzer, M | 1 |
| Yardley, V | 1 |
| Becker, K | 1 |
| Davioud-Charvet, E | 1 |
| Plouffe, D | 2 |
| Brinker, A | 1 |
| McNamara, C | 2 |
| Henson, K | 1 |
| Kato, N | 2 |
| Kuhen, K | 2 |
| Nagle, A | 3 |
| Adrián, F | 1 |
| Matzen, JT | 1 |
| Anderson, P | 1 |
| Nam, TG | 2 |
| Gray, NS | 1 |
| Chatterjee, A | 2 |
| Janes, J | 1 |
| Yan, SF | 1 |
| Trager, R | 1 |
| Caldwell, JS | 1 |
| Schultz, PG | 2 |
| Zhou, Y | 2 |
| Winzeler, EA | 3 |
| Dow, GS | 1 |
| Chen, Y | 1 |
| Andrews, KT | 1 |
| Caridha, D | 3 |
| Gerena, L | 3 |
| Gettayacamin, M | 4 |
| Johnson, J | 2 |
| Li, Q | 3 |
| Melendez, V | 2 |
| Obaldia, N | 1 |
| Tran, TN | 1 |
| Kozikowski, AP | 1 |
| Opsenica, I | 2 |
| Lanteri, CA | 2 |
| Anova, L | 1 |
| Khan, MO | 1 |
| Levi, MS | 1 |
| Tekwani, BL | 1 |
| Khan, SI | 1 |
| Kimura, E | 1 |
| Borne, RF | 1 |
| O'Neill, PM | 2 |
| Park, BK | 2 |
| Shone, AE | 2 |
| Maggs, JL | 2 |
| Roberts, P | 2 |
| Stocks, PA | 2 |
| Biagini, GA | 1 |
| Bray, PG | 2 |
| Gibbons, P | 1 |
| Berry, N | 2 |
| Winstanley, PA | 2 |
| Mukhtar, A | 1 |
| Bonar-Law, R | 1 |
| Hindley, S | 2 |
| Bambal, RB | 2 |
| Davis, CB | 2 |
| Bates, M | 2 |
| Hart, TK | 1 |
| Gresham, SL | 2 |
| Lawrence, RM | 1 |
| Brigandi, RA | 2 |
| Gomez-delas-Heras, FM | 1 |
| Gargallo, DV | 2 |
| Ward, SA | 2 |
| Stanford, D | 1 |
| Nixon, G | 1 |
| Asadollahy, E | 1 |
| Biagini, G | 1 |
| Davies, J | 1 |
| Hall, C | 1 |
| Rimmer, K | 1 |
| Gomez-de-Las-Heras, FM | 1 |
| Parapini, S | 1 |
| Vivas, L | 1 |
| Lander, H | 1 |
| Taramelli, D | 2 |
| Nasveld, PE | 1 |
| Edstein, MD | 1 |
| Reid, M | 1 |
| Brennan, L | 1 |
| Harris, IE | 1 |
| Kitchener, SJ | 1 |
| Leggat, PA | 1 |
| Pickford, P | 1 |
| Kerr, C | 1 |
| Ohrt, C | 1 |
| Prescott, W | 1 |
| Nzila, A | 1 |
| Rottmann, M | 4 |
| Chitnumsub, P | 1 |
| Kiara, SM | 1 |
| Kamchonwongpaisan, S | 1 |
| Maneeruttanarungroj, C | 1 |
| Taweechai, S | 1 |
| Yeung, BK | 2 |
| Goh, A | 3 |
| Lakshminarayana, SB | 3 |
| Zou, B | 2 |
| Wong, J | 1 |
| Ma, NL | 1 |
| Weaver, M | 1 |
| Keller, TH | 2 |
| Dartois, V | 3 |
| Wittlin, S | 1 |
| Brun, R | 3 |
| Yuthavong, Y | 1 |
| Diagana, TT | 3 |
| Lee, MC | 2 |
| Russell, B | 2 |
| Seitz, P | 1 |
| Plouffe, DM | 2 |
| Dharia, NV | 2 |
| Tan, J | 1 |
| Cohen, SB | 1 |
| Spencer, KR | 1 |
| González-Páez, GE | 1 |
| Suwanarusk, R | 1 |
| Jegla, T | 1 |
| Schmitt, EK | 1 |
| Beck, HP | 1 |
| Nosten, F | 1 |
| Renia, L | 1 |
| Fidock, DA | 2 |
| Siswantoro, H | 1 |
| Ratcliff, A | 1 |
| Prasetyorini, B | 1 |
| Chalfein, F | 1 |
| Marfurt, J | 1 |
| Kenangalem, E | 1 |
| Wuwung, M | 1 |
| Piera, KA | 1 |
| Ebsworth, EP | 1 |
| Anstey, NM | 1 |
| Tjitra, E | 1 |
| Price, RN | 1 |
| Burnett, JC | 1 |
| Gussio, R | 1 |
| Todorović, N | 1 |
| Sciotti, RJ | 1 |
| Basilico, N | 1 |
| Nuss, JE | 1 |
| Wanner, L | 1 |
| Panchal, RG | 1 |
| Bavari, S | 1 |
| Gujjar, R | 1 |
| El Mazouni, F | 1 |
| White, KL | 2 |
| White, J | 1 |
| Creason, S | 1 |
| Shackleford, DM | 2 |
| Deng, X | 1 |
| Charman, WN | 1 |
| Bathurst, I | 2 |
| Burrows, J | 1 |
| Floyd, DM | 1 |
| Matthews, D | 1 |
| Charman, SA | 2 |
| Phillips, MA | 1 |
| Rathod, PK | 1 |
| Ndakala, AJ | 1 |
| Gessner, RK | 1 |
| Gitari, PW | 1 |
| October, N | 1 |
| Hudson, A | 1 |
| Fakorede, F | 1 |
| Kaiser, M | 1 |
| Yeates, C | 1 |
| Chibale, K | 1 |
| Wu, T | 2 |
| Gagaring, K | 2 |
| Borboa, R | 2 |
| Francek, C | 1 |
| Chen, Z | 1 |
| Wu, J | 1 |
| Ang, HQ | 1 |
| Zeng, P | 1 |
| Kang, ML | 1 |
| Tan, W | 1 |
| Tan, M | 1 |
| Ye, N | 1 |
| Lin, X | 1 |
| Caldwell, C | 1 |
| Ek, J | 1 |
| Skolnik, S | 1 |
| Liu, F | 1 |
| Wang, J | 1 |
| Chang, J | 1 |
| Li, C | 1 |
| Hollenbeck, T | 1 |
| Tuntland, T | 2 |
| Isbell, J | 1 |
| Fischli, C | 1 |
| Keller, T | 1 |
| Diagana, T | 1 |
| Winzeler, E | 1 |
| Glynne, R | 1 |
| Tully, DC | 1 |
| Chatterjee, AK | 1 |
| Milner, E | 1 |
| Gardner, S | 1 |
| Moon, J | 1 |
| Grauer, K | 1 |
| Auschwitz, J | 1 |
| Kozar, M | 1 |
| Lee, P | 1 |
| Leed, S | 1 |
| McCalmont, W | 1 |
| Roncal, N | 1 |
| Sciotti, R | 1 |
| Smith, B | 1 |
| Sousa, J | 1 |
| Tungtaeng, A | 1 |
| Wipf, P | 1 |
| Dow, G | 1 |
| Sá, MS | 1 |
| de Menezes, MN | 1 |
| Krettli, AU | 1 |
| Ribeiro, IM | 1 |
| Tomassini, TC | 1 |
| Ribeiro dos Santos, R | 1 |
| de Azevedo, WF | 1 |
| Soares, MB | 1 |
| Meister, S | 1 |
| Kuhen, KL | 1 |
| Bonamy, GM | 1 |
| Barnes, SW | 1 |
| Bopp, SE | 1 |
| Bright, AT | 1 |
| Che, J | 1 |
| Cohen, S | 1 |
| Gordon, P | 1 |
| Groessl, T | 1 |
| McNamara, CW | 1 |
| Richmond, W | 1 |
| Roland, J | 1 |
| Zhou, B | 1 |
| Froissard, P | 1 |
| Glynne, RJ | 1 |
| Mazier, D | 1 |
| Sattabongkot, J | 1 |
| Walker, JR | 1 |
| Zhu, S | 1 |
| Chandrashekar, G | 1 |
| Meng, L | 1 |
| Robinson, K | 1 |
| Chatterji, D | 1 |
| Conyers, RC | 1 |
| Mazzone, JR | 1 |
| Siegler, MA | 1 |
| Tripathi, AK | 1 |
| Sullivan, DJ | 1 |
| Mott, BT | 1 |
| Posner, GH | 1 |
| Korotchenko, V | 1 |
| Sathunuru, R | 1 |
| Kreishman-Deitrick, M | 1 |
| Smith, PL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
| Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094] | Phase 4 | 388 participants (Anticipated) | Interventional | 2023-06-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for mefloquine hydrochloride and Malaria
| Article | Year |
|---|---|
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male | 2010 |
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male | 2010 |
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male | 2010 |
Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.
Topics: Adult; Aminoquinolines; Antimalarials; Australia; Double-Blind Method; Female; Humans; Malaria; Male | 2010 |
26 other studies available for mefloquine hydrochloride and Malaria
| Article | Year |
|---|---|
Arteether, a new antimalarial drug: synthesis and antimalarial properties.
Topics: Animals; Antimalarials; Artemisinins; Magnetic Resonance Spectroscopy; Malaria; Mice; Models, Molecu | 1988 |
Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.
Topics: Administration, Oral; Animals; Antimalarials; Artemisinins; Drug Evaluation, Preclinical; Drug Resis | 2002 |
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
Topics: Alkyl and Aryl Transferases; Animals; Antimalarials; Cells, Cultured; Electrophoresis, Polyacrylamid | 2005 |
Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives.
Topics: Administration, Oral; Animals; Antimalarials; Carbamates; Guanidines; Imidazoles; Imidazolidines; Ma | 2005 |
Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.
Topics: Administration, Oral; Amination; Animals; Antimalarials; Artemisinins; Drug Resistance, Multiple; He | 2006 |
Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives(1).
Topics: Animals; Antimalarials; Antineoplastic Agents; Cell Line, Tumor; Crystallography, X-Ray; Cyclohexane | 2007 |
Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.
Topics: Animals; Antimalarials; Biological Transport; Cell Line, Tumor; Chloroquine; Drug Resistance; Drug T | 2008 |
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
Topics: Animals; Antimalarials; Cluster Analysis; Computational Biology; Drug Evaluation, Preclinical; Drug | 2008 |
Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.
Topics: Animals; Antimalarials; Aotidae; Drug Resistance; Enzyme Inhibitors; Histone Deacetylase Inhibitors; | 2008 |
New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton.
Topics: Aminoquinolines; Animals; Antimalarials; Binding Sites; Disease Models, Animal; Dose-Response Relati | 2008 |
Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Cyclams; Hemeproteins; Heterocyclic Compounds; | 2009 |
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Benzylamines; Cytochrome P-450 Enzyme Inhibito | 2009 |
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
Topics: Aminoquinolines; Amodiaquine; Animals; Antimalarials; Cell Survival; Chloroquine; Dogs; Drug Resista | 2009 |
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
Topics: Administration, Oral; Animals; Antimalarials; Biological Availability; Drug Resistance; Female; Foli | 2010 |
Spiroindolones, a potent compound class for the treatment of malaria.
Topics: Adenosine Triphosphatases; Animals; Antimalarials; Cell Line; Drug Discovery; Drug Resistance; Eryth | 2010 |
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Female; Humans; Indonesia; M | 2011 |
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.
Topics: Animals; Anopheles; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Botulinum Toxins, Type A | 2011 |
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
Topics: Animals; Antimalarials; Dihydroorotate Dehydrogenase; Disease Models, Animal; Drug Design; Drug Disc | 2011 |
Antimalarial pyrido[1,2-a]benzimidazoles.
Topics: Administration, Oral; Animals; Antimalarials; Benzimidazoles; Drug Resistance, Multiple; Humans; In | 2011 |
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
Topics: Amino Acids; Aniline Compounds; Animals; Antimalarials; Benzene Derivatives; Cell Line; Drug Resista | 2011 |
Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum.
Topics: Animals; Antimalarials; Cell Line; Cell Membrane Permeability; Dimerization; Dogs; Drug Resistance; | 2011 |
Antimalarial activity of physalins B, D, F, and G.
Topics: Animals; Antimalarials; Immunosuppressive Agents; Malaria; Mice; Mice, Inbred BALB C; Parasitemia; P | 2011 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resista | 2011 |
Febrifugine analogue compounds: synthesis and antimalarial evaluation.
Topics: Animals; Antimalarials; Aotus trivirgatus; Drug Evaluation, Preclinical; Malaria; Piperidines; Plasm | 2012 |
The survival times of malaria-infected mice are prolonged more by several new two-carbon-linked artemisinin-derived dimer carbamates than by the trioxane antimalarial drug artemether.
Topics: Animals; Antimalarials; Artemether; Artemisinins; Carbamates; Carbon; Crystallography, X-Ray; Dimeri | 2014 |
Antimalarial activity of 4-amidinoquinoline and 10-amidinobenzonaphthyridine derivatives.
Topics: Animals; Antimalarials; Hep G2 Cells; Humans; Malaria; Malaria, Falciparum; Male; Mice; Naphthyridin | 2015 |